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INTRODUCTION
Heart failure (HF) occurs when heart capacity is insuf-
ficient to supply an adequate perfusion for peripheral 
demands. When uncompensated, it can cause several 
systemic repercussions, depending on its presentation. 
A patient might have only low cardiac debit, or might have 
great pulmonary vascular congestion, causing acute lung 
edema and significant dyspnea.   
Nesiritide is the recombinant form of the brain natri-
uretic peptide (BNP), which is secreted when the walls of 
the cardiac ventricles are distended, and was approved for 
use by the Food and Drug Administration (FDA) in 2001 
for the treatment of uncompensated HF. It has vasodilating 
properties, causing a decrease in the pre and post-charge, 
a decrease in pulmonary capillary pressure, an increase in 
cardiac debit without inotropic1,2 effects and without caus-
ing arrhythmias3.
This review aims to evaluate whether there is benefit 
or damage in the use of nesiritide in patients presenting to 
emergency rooms with uncompensated HF dyspnea.
METHOD
A systematic review of the MEDLINE database was per-
formed, searching for the best available evidence, with the 
following strategy: [(natriuretic peptide, brain OR nesirit-
ide) AND (dyspnea OR heart failure)]. The “therapy/nar-
row” filter was used through the clinical queries interface.
Each study retrieved was analyzed by title and sum-
mary. The studies selected met the following inclusion 
criteria: consist in a randomized clinical trial, compare 
the use of nesiritide to placebo (both combined with 
standard therapy) in patients presenting to the emergen-
cy room with uncompensated HF/dyspnea and be writ-
ten in English, Spanish, or Portuguese. Only studies scor-
ing three or higher in the score elaborated by Jadad et al.4 
were included in the final selection and data analysis.
All the variables were analyzed by using the differ-
ence of absolute risk (AR), with its confidence interval of 
95% (95% CI) and the number needed to treat  (NNT) 
Figure 1 – Dyspnea after 8 hours.
*Meta-analysis of the studies selected which were expressed in dychotomous data. Global result expressed in difference of absolute risk, demonstrating an absolute 
risk reduction (ARR) of 0.04 (95% CI: 0.01-0.06) and NNT = 25.
Nesiritide Placebo           Risk difference Risk difference
Study or subgroup Events Total Events Total Weight         M-H, Fixed, 95% CI M-H, Fixed, 95% CI
O’Connor et al.6 1982 3564 2071 3777 96.4% -0.02 [-0.05, 0.00]
Miller et al.7 8 53 25 48 1.4% -0.37 [-0.54, -0.20]
Colucci et al.9 (0,015 μg) 19 43 37 42 1.1% -0.44 [-0.62, -0.26]
Colucci et al.9 (0,03 μg) 21 42 37 42 1.1% -0.38 [-0.56, -0.20]
Total (95% CI) 3702 3709 100.0% -0.04 [-0.06, -0.01]
Total events 2030 2170
Heterogeneity: Chi2 = 49.68, df= 3 (p < 0.00001); I 2 = 94%
Test of overall effects: Z = 3.18 (p = 0.001) Nesiritide
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Figure 2 – Heterogeneity test.
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* Funnel Plot – Analysis demonstrating a great heterogeneity among the studies analyzed 
(the heterogeneous studies are out of the funnel area).
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Figure 3 – Symptomatic hypotension.
* Meta-analysis of the selected studies. Global result expressed in the difference of absolute risk, demonstrating an absolute risk increase (ARI) of 0.03  
(95% CI: 0.02-0.04) and NNH = 33.
Nesiritide Placebo           Risk difference Risk difference
Study or subgroup Events Total Events Total Weight         M-H, Fixed, 95%  CI M-H, Fixed, 95%  CI
O’Connor et al.6 250 3564 141 3777 92.5% 0.03 [-0.02, 0.04]
Peacock et al.8 5 127 1 123 3.2% 0.03 [-0.01, 0.07]
Colucci et al.9 (0,015 μg) 2 43 0 42 1.1% 0.05 [-0.03, 0.12]
Colucci et al.9 (0,03 μg) 5 42 0 42 1.1% 0.12 [0.01, 0.22]
Mills et al.10 (0,015 μg) 1 22 2 29 0.6% -0.02 [-0.15, 0.10]
Mills et al.10 (0,03 μg) 1 26 2 29 0.7% -0.03 [-0.15, 0.09]
Mills et al.10 (0,06 μg) 4 26 2 29 0.7% 0.08 [-0.08, 0,25]
Total (95% CI) 3850 3871 100.0% 0.03 [0.02, 0.04]
Total events 268 148
Heterogeneity: Chi2 = 5.03, df= 6 (p = 0.54); I 2 = 0%
Test of overall effects: Z = 6.13 (p < 0.00001) Favours nesiritide
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Figure 4 – Heterogeneity test.
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* Funnel Plot demonstrating homogeneity among the studies.
or the number needed to harm (NNH), through the Cat-
maker soware. The Review Manager 5.1.2. soware was 
used for a meta-analysis.
RESULTS
The literature review was concluded on August, 2011. 
Four hundred and eleven articles were retrieved and only 
seven5-11 of them met the inclusion criteria. Afier analyz-
ing the selected articles, two of them were excluded from 
the final selection; one5 because it did not use a placebo 
in the comparison group and the other11 for not provid-
ing the absolute data about the outcomes at stake, mak-
ing it impossible to calculate the risk difference.
In a study by Colucci et al.9 two doses (0.015 and 
0.030 fig/kg/min) were tested in comparison with place-
bo. In a study by Mills et al.10 three doses (0.015, 0.03 and 
0.06 fig/kg/min) were tested in comparison with placebo.
DYSPNEA
Nesiritide demonstrated benefit, with an absolute 
risk reduction (ARR) of 0.04 (95% CI: 0.01-0.06) and 
NNT = 25 (Figure 1). However, the sensitivity analysis 
reveals that when the studies responsible for the high 
heterogeneity7,9 (Figure 2) are excluded from the meta-
analysis, the global effect should be similar to the effect of 
the study performed by O’Connor et al.6, that is, it should 
not demonstrate a significant benefit. 
The study by Peacock et al.8 cannot be added to the 
meta-analysis because it is expressed in averages. Howev-
er, the difference in the averages between the two groups 
afier nesiritide infusion was not statistically significant. 
SYMPTOMATIC HYPOTENSION
Nesiritide demonstrated an absolute risk increase (ARI) 
of symptomatic hypotension of 0.03 (95% CI: 0.02-0.04), 
with NNH = 33 (Figures 3 and 4).
RENAL FUNCTION
Only two studies6,7 evaluated the evolution of the renal 
function. The study by O’Connor et al.6 used as a param-
eter for the worsening of renal function a decrease higher 
or equal to 25% in the basal glomerular filtration rate; 
the study by Miller et al.7 used the criterion of increase of 
1.5 mg/dL or more in the basal serum creatinine. How-
ever, no significant difference was observed among the 
groups in either study.
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CONCLUSION
According to an analysis of the best available evidence, 
we concluded that nesiritide did not demonstrate a sig-
nificant benefit in the improvement of dyspnea, besides 
demonstrating a discrete increase in the risk of symp-
tomatic hypotension.
Therefore, up to the present moment, there are no evi-
dences that support a routine use of nesiritide for reliev-
ing dyspnea in patients suffering from uncompensated HF 
presenting to emergency rooms.
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